Completed OBSERVATIONAL NCT02194881

Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation (IVACAFTOR1)

Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation - Efficacy and Safety Results After the First Year of Treatment in the Real Life Setting.

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions Cystic Fibrosis

Interventions CF patients with a G551D mutation and treated with Ivacaftor

Updated 8 times since 2017 Last updated: Mar 4, 2026 Started: Oct 31, 2014 Primary completion: Feb 29, 2016 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Cystic Fibrosis and is currently completed. Assistance Publique - Hôpitaux de Paris leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Mar 2026 — Present [monthly]

Completed
Dec 2025 — Mar 2026 [monthly]

Completed
Sep 2024 — Dec 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin
Vaincre la Mucoviscidose

Data source: Assistance Publique - Hôpitaux de Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France